NMN is one of the fastest-growing supplement enquiries in UK community pharmacies. Patients — particularly those aged 45 and over — are increasingly asking about NAD+ precursors after exposure to media coverage, GP recommendations and the growing longevity science conversation.

Little Ox is uniquely positioned for pharmacy retail: founded by a practising NHS GP, independently certified to pharmaceutical manufacturing standards, with quality documentation that meets the bar pharmacists need to recommend a product with confidence.

Why NMN Belongs on Pharmacy Shelves

Community pharmacies already stock CoQ10, resveratrol, magnesium and other cellular health supplements. NMN is the next logical addition — it addresses a biological mechanism (NAD+ decline) that is now well-documented in peer-reviewed literature, increasingly discussed by the patients you see.

The 2021 clinical trial published in Science found significant improvement in muscle insulin sensitivity in postmenopausal women. A 2022 trial showed improved aerobic capacity in older adults. The evidence base is sufficiently robust for confident pharmacy recommendation at the 500mg dose.

What Pharmacists Get With Little Ox

• A product they can defend: independently tested purity of 95.8% (Eurofins, HPLC-DAD) confirmed by independent third-party laboratory. Zero heavy metals detected. GMP certified by Intertek to 21 CFR Part 111.
• A founder they can reference: Dr Chun Tang — MBChB (Manchester), MRCGP, 26 years NHS and private GP practice. Media presence in The Telegraph, The Mirror, The Independent and Women's Health.
• A price that doesn't lose customers: £7.99/month retail — significantly lower than the £25–70 alternatives, which means patients who ask about NMN can actually afford to continue taking it.
• Clinical summary materials: Product information for staff on the NMN mechanism of action, dosing, safety profile and patient suitability. Available on request.

Safety Profile

Human clinical trials have consistently shown NMN to be well-tolerated at doses of 250–500mg daily. No significant adverse effects have been reported in trials to date. NMN should be used with caution in patients with active oncological diagnoses (NAD+ supports all cellular processes, including in less healthy cells) and is not recommended in pregnancy or breastfeeding due to lack of data rather than known harm.

Full safety documentation and references are available on request for pharmacy staff training.

← Wholesale overview View quality certifications →